New Treatment Strategies in Aggressive B-Cell Lymphomas: Advances, Application, and a Glimpse of the Future

Learn how the experts are individualizing treatment selection and managing adverse events associated with established and emerging therapies for patients with MCL and DLBCL in this program centered around a dynamic live symposium at ASCO 2022. Download slides and watch the on-demand webcast from the live symposium read an expert-authored commentary and download a clinical summary resource for the discussed agents.

Share

Program Content

Activities

MCL: Biomarkers and Treatment
Biomarkers for Risk Stratification and Treatment Selection for Patients With MCL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

View Activity
Frontline Treatment of DLBCL
Frontline Treatment Considerations and Strategies for Patients With Newly Diagnosed DLBCL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

View Activity
Relapsed/Refractory DLBCL
Selection and Sequencing of Available, New, and Emerging Agents for Relapsed/Refractory DLBCL
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2022

Expires: June 04, 2023

View Activity

Activities

ADCs for B-Cell Lymphomas
Antibody–Drug Conjugates for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
Bispecific Abs for B-Cell Lymphomas
Bispecific Antibodies for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
BTKi for B-Cell Lymphomas
BTK Inhibitors for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
CAR T-cells for B-Cell Lymphomas
CAR T-cell Therapy for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
IMiDs and ICIs for B-Cell Lymphomas
Immunomodulatory Agents and Immune Checkpoint Inhibitors for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
Ab-Based Tx for B-cell Lymphomas
Antibody-Based Therapies for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity
XPO1 Inhibitors for B-Cell Lymphomas
XPO1 and Nuclear Export Inhibitors for Aggressive B-Cell Lymphomas: A Summary Resource
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: June 06, 2022

Expires: June 05, 2023

View Activity

Activities

Aggressive B-Cell
New Treatment Strategies in Aggressive B-Cell Lymphomas: Advances, Application, and a Glimpse of the Future
Multimedia
Congratulations: You achieved a completion on 04/09/2022

Released: June 08, 2022

Expires: June 07, 2023

View Activity

Activities

FAQs: Tx for MCL and DLBCL
FAQs: Incorporating Novel and Emerging Treatment Combinations Into the Management of Aggressive B-Cell Lymphomas
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: July 28, 2022

Expires: July 27, 2023

View Activity

Faculty

cover img faculity

Julie M. Vose, MD

Neumann M. and Mildred E. Harris Professor
Chief
, Section of Hematology/Oncology
Professor of Medicine
University of Nebraska Medical Center
Omaha, Nebraska

cover img faculity

Jeremy S. Abramson, MD, MMSc

Director, Hagler Center for Lymphoma
Massachusetts General Hospital
Associate Professor of Medicine
Harvard Medical School
Boston, MA

cover img faculity

Grzegorz Nowakowski, MD

Professor of Medicine and Oncology
Department of Hematology
Mayo Clinic
Rochester, Minnesota

Provided by

ProCE Banner

Supporters

Supported by educational grants from

AbbVie

Bristol Myers Squibb

Genmab US

Incyte Corporation

Lilly